Lunit has partnered with Fujifilm Thailand and Microsoft to bring its AI radiology solutions to Bumrungrad International Hospital, a private hospital in Bangkok.
According to a press release, Lunit uses its INSIGHT CXR chest X-ray analysis software and INSIGHT MMG mammography tool in the hospital.
Along with Fujifilm Thailand, Lunit will deliver its AI solutions to Bumrungrad using Microsoft Azure, which the company says will improve the operation of its software.
WHY IT MATTERS
With 580 beds, Bumrungrad is one of the largest private hospitals in Southeast Asia and treats over a million patients in 190 countries every year.
The hospital aims to provide better services through the timely detection of breast abnormalities and breast cancer using AI.
“AI would be a supportive tool for human decision making and provide a second opinion for physicians during the diagnostic process,” said Dr. Teeradache Viangteeravat, R&D Director of Bumrungrad.
Currently, the hospital uses the Lunit AI solutions in its check-ups, intensive care units and emergency rooms. INSIGHT CXR and INSIGHT MMG have so far analyzed more than 100,000 images taken in the hospital every year.
Bumrungrad also expects that the AI solutions will help “accelerate the learning curve for young doctors with less experience reading images.”
Lunit said it plans to continue supporting Bumrungrad to “drive breakthrough medical innovations across Southeast Asia.”
THE BIGGER TREND
A similar deployment agreement was signed between Lunit and the Egypt-based company earlier this year Baheya Foundation. The non-profit charity group that provides free care to breast cancer patients chose Lunit INSIGHT MMG.
In addition, Lunit recently received its chest x-ray and mammography solutions cleared for market release in Canada. This followed last year’s US Food and Drug Administration approval for the same AI products.
Last month, Lunit filed a registration statement with the Korean Stock Exchange for a July IPO. The company plans to issue a total of 1.12 million shares at between $34 and $38 a share.